Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex for macular edema due to retinal vein occlusion
2011-000425-72Phase 4Completed
- Sponsor
- Fondazione G.B. Bietti-IRCCS
- Start
- May 2011
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ozurdex in Vein occlusion (RVO), central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), sponsored by Fondazione G.B. Bietti-IRCCS. Primary endpoint: Improvement in visual acuity. Started May 2011; status: completed.
02
Drugs
ozurdex
03
Conditions
Vein occlusion (RVO)central retinal vein occlusion (CRVO)branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on 2011-000425-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000425-72.